For the Inventor, By the Inventor

Enter assignee name

Bothell, WA, United States of America

Seagen Inc.

USPTO Granted Patents = 66

% Expired Patents = 4.5

CIPO Patents = 4

EPO Patents = 21

Trademarks = 21

Forward Citations = 49

Loading Chart...

Loading Chart...

97 inventors (with patents filed for the assignee):

Lori Westendorf (9 out of 11 patents)

Shyra Gardai (7 out of 8 patents)

Django Sussman (7 out of 20 patents)

4. Patrick J Burke (7 out of 26 patents)

5. Dana Kennedy (6 out of 12 patents)

6. Peter Senter (6 out of 47 patents)

7. Eric Sievers (5 out of 16 patents)

8. Che-Leung Law (5 out of 20 patents)

9. Robert Lyon (5 out of 8 patents)

10. Scott Peterson (4 out of 6 patents)

11. Scott C Jeffrey (4 out of 30 patents)

12. Karen Jane Meyrick Morrison (4 out of 68 patents)

13. Vivian Trang (4 out of 4 patents)

14. Matthew R Levengood (4 out of 4 patents)

15. Travis Biechele (4 out of 4 patents)

Core Competencies:

Antibody Drug Conjugates

CD30

HER2

PI3K-AKT

Auristatin

BCMA

CD47

Fucosylation

Tumor Treatment

Drug Linkers

Combination Therapy

Glycan-Interacting

66 patents: Sort by Forward Citations

1. 12590968 - Detection and treatment of CD30+ cancers (2026-03-31),

2. 12496353 - SYNERGISTIC EFFECTS BETWEEN AURISTATIN-BASED ANTIBODY DRUG CONJUGATES AND INHIBITORS OF THE PI3K-AKT MTOR PATHWAY (2025-12-16),

3. 12421312 - Anti-PD-L1 antibodies and antibody-drug conjugates (2025-09-23),

4. 12268751 - Anti-αVβ6 antibodies and antibody-drug conjugates (2025-04-08),

5. 12257340 - Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof (2025-03-25),

6. 12257281 - Hydrophilic antibody-drug conjugates (2025-03-25),

7. 12194321 - Camptothecin conjugates (2025-01-14),

8. 12071480 - CD47 antibodies and uses thereof for treating cancer (2024-08-27),

9. 12048698 - Treatment of HER2 positive cancers (2024-07-30),

10. 12036286 - Selective drug release from internalized conjugates of biologically active compounds (2024-07-16),

11. 11944689 - Drug conjugates with self-stabilizing linkers having improved physiochemical properties (2024-04-02),

12. 11938194 - Cysteine mutated antibodies for conjugation (2024-03-26),

13. 11931414 - Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates (2024-03-19),

14. 11891644 - T cells with reduced surface fucosylation and methods of making and using the same (2024-02-06),

15. 11857565 - Hydrophobic Auristatin F compounds and conjugates thereof (2024-01-02),

Seagen Inc., formerly known as Seattle Genetics, is a biotechnology company that specializes in the development of targeted therapies for the treatment of cancer. The company uses its proprietary antibody-drug conjugate (ADC) technology to create innovative cancer treatments. Seagen focuses on advancing novel therapies that have the potential to improve patient outcomes and transform cancer treatment. With a commitment to scientific excellence and collaboration, Seagen is dedicated to making a meaningful impact in the lives of cancer patients.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 22 2026

66 Patents

#8 in Bothell, WA

#112 in Washington

#5,518 in US

#11,144 in the World

Bothell, WA, United States of America

Seagen Inc.

Forward Citations = 49

97 inventors:

Lori Westendorf (9 out of 11 patents)

Shyra Gardai (7 out of 8 patents)

Django Sussman (7 out of 20 patents)

4. Patrick J Burke (7 out of 26 patents)

5. Dana Kennedy (6 out of 12 patents)

Please report any incorrect information to [email protected]

Loading…